{"preliminary_commentary":{"by_channel":{"youtube":77,"x_thread":61,"podcast":54},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01272037\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT01272037","nct_id":"NCT01272037","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01272037. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.","label":"Arm I (chemotherapy and endocrine therapy)","type":"EXPERIMENTAL"},{"description":"Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.","label":"Arm II (endocrine therapy)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-01-08","type":"ESTIMATED"},"conditions":["Breast Ductal Carcinoma In Situ","Invasive Breast Carcinoma","Multicentric Breast Carcinoma","Multifocal Breast Carcinoma","Synchronous Bilateral Breast Carcinoma"],"enrollment":{"count":5018,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Anastrozole","otherNames":["Anastrazole","Arimidex","ICI D1033","ICI-D1033","ZD-1033"],"type":"DRUG"},{"name":"Exemestane","otherNames":["Aromasin","FCE-24304"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Letrozole","otherNames":["CGS 20267","CGS-20267","CGS20267","Femara","Fempro"],"type":"DRUG"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Systemic Chemotherapy","otherNames":[],"type":"DRUG"},{"name":"Tamoxifen Citrate","otherNames":["Apo-Tamox","Clonoxifen","Dignotamoxi","Ebefen","Emblon","Estroxyn","Fentamox","Gen-Tamoxifen","Genox","ICI 46,474","ICI 46474","ICI-46474","ICI46474","Jenoxifen","Kessar","Ledertam","Lesporene","Nolgen","Noltam","Nolvadex","Nolvadex-D","Nourytam","Novo-Tamoxifen","Novofen","Noxitem","Oestrifen","Oncotam","PMS-Tamoxifen","Soltamox","TAM","Tamax","Tamaxin","Tamifen","Tamizam","Tamofen","Tamoxasta","Tamoxifeni Citras","Zemide"],"type":"DRUG"}],"last_update":"2026-10-22","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Invasive Disease-Free Survival (IDFS)","timeFrame":"5 years after randomization"}],"references":[{"citation":"Abdou Y, Hoag J, Barlow WE, Albain KS, Gralow JR, Meric-Bernstam F, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Schott AF, Racz J, Baehner FL, Tripathy D, Hortobagyi GN, Pusztai L, Sharma P, Kalinsky K. Recurrence Score(R) gene group components and outcomes in the RxPONDER trial (SWOG S1007). J Natl Cancer Inst. 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221. Online ahead of print.","pmid":"42458791","type":"DERIVED"},{"citation":"Kang IM, Forschmiedt JK, Loch MM, Lew DL, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Baehner R, Sharma P, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. JAMA Oncol. 2026 Feb 1;12(2):159-166. doi: 10.1001/jamaoncol.2025.5220.","pmid":"41379459","type":"DERIVED"},{"citation":"Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 1;117(5):889-897. doi: 10.1093/jnci/djae314.","pmid":"39656951","type":"DERIVED"},{"citation":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.","pmid":"34914339","type":"DERIVED"}],"start_date":{"date":"2011-02-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","url":"https://clinicaltrials.gov/study/NCT01272037"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01272037"}